Trefoil factor 2 Antibodies

Trefoil factor 2 (TFF2)

Inhibits gastrointestinal motility and gastric acid secretion. Could be a structural component of gastric mucus, possibly by stabilizing glycoproteins from the mucous membranes through connections with carbohydrate side chains (By similarity).

. .

Gene Information

Human
Gene Name:	TFF2
Uniprot:	Q03403
Entrez:	7032

Family

Belongs to:
No superfamily

Alternative Names

SML1; SML1trefoil factor 2, SML1, human spasmolytic polypeptide (SP)10spasmolytic protein 1; SP; Spasmolysin; Spasmolytic Polypeptide; TFF2; trefoil factor 2

Molecular Weight

Mass (kDA):
14.284 kDA

Genomic Context

Human
Location:	21q22.3
Sequence:	21; NC_000021.9 (42346357..42350994, complement)

Tissue Specificity

Stomach.

Subcellular Localizations

Secreted.

Diseases

• Mucinous Adenocarcinoma
• Malignant Neoplasms
• Stomach Neoplasms
• Metaplasia
• Malignant Neoplasm Of Stomach
• Neoplasms
• Inflammation
• Ulcer
• Carcinoma
• Gastritis
• Hyperplasia
• Helicobacter Infections

• Atrophy
• Cell Transformation, Neoplastic
• Dysplasia
• Adenocarcinoma
• Precancerous Conditions
• Colitis
• Intestinal Diseases

Interacting Proteins

• FCRL4

Pathways

• Secretion
• Localization
• Cell Migration
• Wound Healing
• Pathogenesis
• Cell Proliferation
• Acid Secretion
• Reverse Transcription
• Gastric Acid Secretion
• Regeneration
• Cell Differentiation
• Transdifferentiation
• Immune Response

• Inflammatory Response
• Cell Motility
• Methylation
• Epithelial Cell Migration
• Circadian Rhythm
• Lung Development
• Epithelial Cell Proliferation

PTMs

• Phosphorylation
• Methylation
• Glycosylation

• Demethylation
• Cleavage
• Nitration

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/TFF2

Best Uses Of The TFF2 Marker For GAS

The TFF2 marker is a promising marker to test for GAS. In this article, you'll learn how this marker will work with HIK1083 to differentiate GAS from other types of ECA and transporter-based isotopes to identify RR-DTC metastases. Boster Bio offers many optimization tips to help you get the most benefit from your experiments.

TFF2 is a promising surrogate marker to confirm the diagnosis of GAS

TFF2 is a promising surrogacy indicator for confirming a diagnosis of GAS. It is a highly specific marker of gastric-type discrimination, which makes it a useful surrogate marker that can differentiate GAS from other types of ECA. Both HIK1083 and TFF2 have the same degree of specificity. This results in double positivity for both markers extremely specific for diagnosing GAS. It is also uncommon in non-GASs.

The study assessed the presence of TFF2 in 50 ECAs and 179 entire sections. It showed that TFF2 was significantly more prevalent in GASs than non-GASs. TFF2 was smaller in TMAs than in whole sections. TFF2 may be a promising alternative marker for GAS diagnosis.

There are only a few studies that validate TFF2 for GAS. There aren't many studies that show good interobserver reproducibility in GAS recognition. Furthermore, preoperative biopsy specimens with a limited number of tumor cells could pose an issue for diagnosis. The growth pattern of GAS is endophytic, forming an enlarged, firm cervix. It is challenging to collect sufficient tumor cells in preoperative biopsy specimens.

TFF2 is a mucin-associated peptide that is widely expressed in the gastric gland , but not in the endocervical glands. This protein was investigated in a clinical trial using tissue microarrays in order to mimic immunohistochemical staining of small biopsies. Despite its inconsistent results, it's a promising surrogate indicator to diagnose GAS.

It can be utilized with HIK1083 to distinguish GAS from other kinds of ECA

MUC-6 is a promising "positive marker" of GAS. When when it is combined with HIK1083, MUC-6 is a good way to differentiate the type of ECA from other types of cancer. It isn't yet a definite marker of GAS however, double positivity can help distinguish it from other ECA kinds. It is possible to see staining which is either negative or focal however, it should be treated with caution.

TFF2 and HIK1083 have been shown to be expressed in GAS. These markers are unable to definitively identify all GAS. However it is possible that focal expression could be detected in biopsy specimens. Surrogate markers were therefore investigated. Claudin-18 and AMACR were immunoreactive in a panel of 75 ECAs and their concentrations were compared to the results of HIK1083 and TFF2.

TFF2 immunohistochemistry may be helpful in the diagnosis of GAS. In addition to immunohistochemistry, TFF2 staining may also help in the assignment of histotype. The histopathological appearance of TFF2 as well as Hik1083 can be helpful in identifying GAS and other types of ECA. It is crucial to determine the cytoplasmic borders between GAS and UEA for diagnosis.

However, confirming the diagnosis of GAS in biopsies of the small cervical area can be challenging, because of the presence of benign mimics. MUC-6, an immunoglobulin molecule found in normal endocervical glands, is also positive in gastric-type ECA. However, this test is not specific enough to distinguish GAS from other types of ECA.

Despite its cytological characteristics gastric type Mucinous Adenocarcinoma is a rare. It is responsible for 20.8 percent of cervical cancers and has a lower overall survival rate than HPVA-ECA. HPV-associated ECA occurs more frequently than Adenocarcinomas. However screening programs for cervical cancer have helped to reduce the incidence.

HIK1083 monoclonal antibody tests common antibodies of enterobacteria. This antigen is produced by two species of Actinobacillus. It can be used in the distinction of GAS from other forms of ECA. Apart from assessing GAS in the lab, HIK1083 may help differentiate the condition from HPV-related ECA.

It can be utilized with transporter-based isotopes for identifying RR-DTC metastases

This study describes the combination of TFF2 and transporter-based isotope-biomarkers to detect metastases of RR-DTC. Bierie, Bryan A. and Sokolov, Artem. Uzunangelov. Vladislav. Brown, Douglas. Kusuma. Bhaskar R. Rajewski. Roger A. Newton.

A brand new peptide marker that targets CCK2R has been investigated to help in the detection of the presence of RR-DTC metastases. It was found that this marker was effective in identifying RR-DTC metastases in a woman aged 75 with persistent MTC.

The TFF2 marker, a ligand-like protein, interacts with the antigen in the tumor. It is able to distinguish RR-DTC from other types of cancer. This marker could have diagnostic and anti-cancer properties. It could also be used to identify early metastases within patients with a history or cancer.

TFF2 is not only a marker for prostate cancer It also contains an overexpressed protein in the prostate's membranes. cancer cells. In several studies, TCs showed high PSMA-targeted radiotracer uptake. PSMA expression was linked to tumor size and vascular invasion. PSMA-targeted theranostics are now being developed to treat these TCs in a patient who has refractory to radioiodinated therapy.

Nine studies were reviewed and concluded that the TFF2 marker could be utilized in conjunction with transporter-based imaging to identify RR-DTC metastases. These studies had a lower sensibility than regular MTC (a kind of NET).

Further research is required to understand the CAG metabolism in TCs and to determine the diagnostic value of amino acid tracer. The PG I/II ratio has been shown to be a more reliable marker than serum TFFs. Although they are in the early stages of development, they have potential as markers to detect RR-DTC metastases.

The TFF2 marker is a member of the thermostable protein family that plays an important role in mucosal protection. This protein family also has oncogenic properties that could be associated with cell expansion, migration, as well as other functions. This protein is found in the gastric goblet cells of the digestive tract. However, the levels of its expression are much lower in other organs.

The biomarker TFF2 is versatile and can be used in conjunction with transporter-based markers to distinguish between RR-DTC metastases. It could enhance the detection and classification of the RR-DTC metastases. Researchers believe that the TFF2 marker can be utilized in the future.

To identify metastases of RR-DTC, the TFF2 marker can be used in conjunction with Isotope-based transporters. Tests. The TFF2 marker, a new marker, is highly effective in detecting metastases among patients suffering from RR-DTC. It can be utilized in conjunction with other tests based on transporters and isotopes as well as imaging to differentiate RR DTC metastases.